Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required)
ID: 353830Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353830

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-004.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity through the Coordinating Center for Type 1 Diabetes TrialNet (TNCC) aimed at supporting clinical trials focused on the prevention of type 1 diabetes (T1D) and the preservation of insulin production. This cooperative agreement, identified as RFA-DK-25-004, seeks to continue the existing project by facilitating a wide range of research activities, including data management and the selection of Clinical Centers, while emphasizing the importance of a Plan for Enhancing Diverse Perspectives (PEDP) to foster inclusivity in research. The funding amount is projected to reach approximately $29.5 million per year, with a maximum project duration of five years, and key deadlines include a letter of intent and full application submissions due by September 16, 2024. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-004.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-DK-25-004-Full-Announcement.html
    RFA-DK-25-004.html
    The National Institutes of Health (NIH) is offering funding through the Coordinating Center for Type 1 Diabetes TrialNet (TNCC) to support clinical trials aimed at preventing type 1 diabetes (T1D) and preserving insulin production. The funding opportunity, numbered RFA-DK-25-004, is a continuation of the existing project and emphasizes collaboration and scientific leadership for ongoing and new intervention studies. The TNCC will handle data management, selection of Clinical Centers, and network administration, with a strong requirement for a Plan for Enhancing Diverse Perspectives (PEDP) to enhance inclusivity in research. Key dates for application submissions include a letter of intent due on September 16, 2024, and full applications also due by the same date. The funding amount intends to reach approximately $29.5 million per year, with a maximum duration of five years for the awarded projects. Eligible applicants include higher education institutions and various nonprofit and government entities situated in North America, with an emphasis on those integrating diverse perspectives. The document enforces strict guidelines regarding application procedures and encourages proactive communication to facilitate efficient trial operations, reflecting a strategic effort to advance T1D prevention and treatment research.
    Similar Opportunities
    Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the Type 1 Diabetes TrialNet Clinical Network Hub (HUB), aimed at enhancing clinical trials focused on the prevention and early intervention of Type 1 Diabetes (T1D). The HUB will coordinate operations across various clinical centers to improve participant screening, recruitment, and retention, with a specific emphasis on increasing diversity among participants, particularly from minority populations. This initiative is critical for addressing the rising incidence of T1D and ensuring inclusivity in research efforts. The funding opportunity has an estimated budget of $750,000 per year from a total allocation of $1,000,000, with a maximum project duration of five years. Applications will be accepted starting September 16, 2024, and must include a Plan for Enhancing Diverse Perspectives (PEDP) to be considered complete. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Precision Medicine for Type 1 Diabetic Nephropathy (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Precision Medicine for Type 1 Diabetic Nephropathy (U01 Clinical Trial Not Allowed)," aimed at establishing Recruitment Sites (RS) for enrolling individuals with Type 1 diabetes (T1D) who are at risk of nephropathy. This initiative seeks applications for a longitudinal cohort study that will involve obtaining kidney biopsies and conducting comprehensive clinical phenotyping, with a focus on ethical practices and inclusivity to enhance understanding of T1D nephropathy and identify potential therapeutic targets. The funding opportunity has a budget of approximately $1.3 million, with individual awards of up to $400,000 in direct costs annually, and key deadlines include a letter of intent due on November 11, 2024, with applications closing on December 10, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Limited Competition for the Continuation of Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical Centers (T1DAPC-CCs) (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Limited Competition Funding Opportunity titled "Continuation of Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical Centers" (T1DAPC-CCs), aimed at establishing a clinical consortium to study diabetes incidence following acute pancreatitis episodes, with a focus on type 1 diabetes. This initiative seeks applications from previously funded Clinical Centers to continue a longitudinal observational study that investigates the incidence, etiology, and risk factors associated with diabetes emerging after acute pancreatitis, emphasizing collaboration among consortium members and effective data collection strategies. The funding amount is capped at $350,000 annually, with a project timeline extending up to five years, and applications are due by November 19, 2024, with the earliest anticipated award start in July 2025. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Single Source for the Continuation of the Type 1 Diabetes in Acute Pancreatitis Consortium - Data Coordinating Center (T1DAPC-DCC) (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is soliciting applications for a cooperative agreement to establish the Type 1 Diabetes in Acute Pancreatitis Consortium Data Coordinating Center (T1DAPC-DCC). The primary objective is to conduct a longitudinal observational study, known as the DREAM study, which will investigate the incidence and mechanisms of diabetes that develop following episodes of acute pancreatitis. This initiative is crucial for understanding the relationship between acute pancreatitis and the onset of diabetes, particularly type 1 diabetes, and aims to identify genetic and environmental risk factors in a diverse population. Interested applicants must submit their proposals by November 19, 2024, with a funding ceiling of $800,000, and can direct inquiries to grantsinfo@nih.gov for further information.
    Notice of Intent to Publish a Funding Opportunity Announcement for Precision Medicine for Type 1 Diabetic Nephropathy (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for a cooperative agreement aimed at advancing research on Type 1 Diabetic nephropathy (T1D). This initiative seeks applications from Recruitment Sites (RS) to enroll adult and pediatric patients with T1D, particularly those at high risk for diabetic nephropathy, into a longitudinal cohort study, which will include protocol-based kidney biopsies. The research will leverage existing resources from the Kidney Precision Medicine Project (KPMP) to create a Kidney Tissue Atlas, identify disease subgroups, and explore novel therapeutic targets. The estimated total program funding for this opportunity is $1.3 million, with the NOFO expected to be published in fall 2024 and applications due in late fall 2024. Interested applicants are encouraged to reach out to the NIDDK contacts provided in the announcement for further information.
    Single Source for the Continuation of the Human Pancreas Analysis Program (HPAP) for Type 1 Diabetes (HPAP-T1D) (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for a cooperative agreement to support the continuation of the Human Pancreas Analysis Program for Type 1 Diabetes (HPAP-T1D) at the University of Pennsylvania. This initiative aims to enhance research on Type 1 Diabetes by systematically collecting and analyzing human pancreatic tissues and immune cells from patients, thereby advancing the understanding of disease mechanisms and identifying potential biomarkers for early intervention. The program is critical for fostering collaborative translational research within the Human Islet Research Network, which seeks innovative strategies to protect and replace functional human beta cell mass. The total funding available is $7.5 million over four years, with applications due by October 24, 2024. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting high-risk observational studies related to diabetes, digestive, kidney, and metabolic diseases. Applicants must complete all planning activities prior to submission, as these cannot be included in the U01 application, and a Plan for Enhancing Diverse Perspectives (PEDP) is mandatory for consideration. This funding opportunity is crucial for advancing clinical research and addressing health disparities, particularly by encouraging collaboration with underrepresented communities. Interested applicants should note that the application deadline is February 5, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIDDK Education Program Grants (R25 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering Research Education Program Grants (R25) to enhance training in biomedical, behavioral, and clinical research. This funding opportunity aims to support educational activities that develop research skills and provide hands-on experiences in areas critical to NIDDK, including diabetes, digestive diseases, and obesity. Eligible applicants include a wide range of organizations such as higher education institutions, non-profits, and local governments, with a funding limit of $100,000 per year for up to five years. The application deadline is January 30, 2024, and interested parties can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the program's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-074.html.
    NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity for high-risk multi-center clinical study implementation planning via Cooperative Agreements (U34). This initiative aims to support the early peer review of proposed clinical studies, assess study designs, and develop essential documentation, including operational manuals, focusing on diseases relevant to NIDDK's mission. The program emphasizes health equity and inclusivity, requiring a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Interested applicants can apply for up to $225,000 per year for a maximum of two years, with the application submission period opening on September 9, 2024, and the closing date set for June 10, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting investigator-initiated, high-risk clinical trials that involve multiple clinical centers. Applicants must propose hypothesis-driven studies that focus on diseases relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), with an emphasis on enhancing diverse perspectives in research. This funding opportunity is crucial for advancing therapeutic studies that can significantly improve clinical practices and public health outcomes. Interested applicants should note that the application period opens on January 5, 2024, with a closing date of November 5, 2026, and are encouraged to consult with NIDDK staff prior to submission. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.